Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allarity Therapeutics (ALLR) Notes Payables (2024 - 2025)

Allarity Therapeutics' Notes Payables history spans 2 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Notes Payables rose 3.7% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 3.7%, while the annual FY2025 figure was $1.4 million, 3.7% up from the prior year.
  • Notes Payables reached $1.4 million in Q4 2025 per ALLR's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $2.7 million in Q1 2024 to a low of $1.3 million in Q2 2024.